Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

The Prime Minister, Justin Trudeau, today issued the following statement on International Women's Day: "Women in Canada have made transformative progress in shaping our country for the better. Today, ...

As the first quarter of 2025 unfolds, China's innovation landscape reveals compelling patterns through three distinct regional narratives. The eastern tech stronghold of Hangzhou continues its ...

"We look forward to sharing new data for ruxolitinib cream (Opzelura ®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic ...

Bank of New York Mellon Corp boosted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 7.5% in the 4th quarter, ...

In addition, Opzelura ® (ruxolitinib) was approved for the treatment of vitiligo in July 2022 and is projected to have sales of >$600 million for that indication in 2030 (EvaluatePharma).

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

It is facing competition in the category from non-steroid drugs like Incyte’s JAK inhibitor Opzelura (ruxolitinib), approved for atopic dermatitis in 2021, although, that requires twice-daily ...